These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M; Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956 [TBL] [Abstract][Full Text] [Related]
5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
6. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States. Ektare V; Lang J; Choi Y; Finelli L Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis. Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182 [TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Tripp RA; Power UF; Openshaw PJM; Kauvar LM J Virol; 2018 Feb; 92(3):. PubMed ID: 29118126 [TBL] [Abstract][Full Text] [Related]
9. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T; N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726 [TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476 [TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Sanders SL; Agwan S; Hassan M; van Driel ML; Del Mar CB Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009417. PubMed ID: 31446622 [TBL] [Abstract][Full Text] [Related]
13. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. Dieussaert I; Hyung Kim J; Luik S; Seidl C; Pu W; Stegmann JU; Swamy GK; Webster P; Dormitzer PR N Engl J Med; 2024 Mar; 390(11):1009-1021. PubMed ID: 38477988 [TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Groothuis JR; Simoes EA; Hemming VG Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741 [TBL] [Abstract][Full Text] [Related]
15. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020. Gantenberg JR; van Aalst R; Zimmerman N; Limone B; Chaves SS; La Via WV; Nelson CB; Rizzo C; Savitz DA; Zullo AR J Infect Dis; 2022 Aug; 226(Suppl 2):S164-S174. PubMed ID: 35968869 [TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus disease: update on treatment and prevention. Krilov LR Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F; Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558 [TBL] [Abstract][Full Text] [Related]
19. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus. Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043 [TBL] [Abstract][Full Text] [Related]
20. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF; N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]